FDA Untitled Letter, sNDA Delay, Amplify Amarin’s Regulatory Woes

Drug Industry Daily
A A
Amarin has received an FDA untitled letter for omitting risk information in a print promotion for its fish oil drug Vascepa, adding to a pileup of setbacks for the product.

To View This Article:

Login

Subscribe To Drug Industry Daily